FINWIRES · TerminalLIVE
FINWIRES

美国油价最新消息:霍尔木兹海峡袭击事件导致原油价格上涨,美国燃料库存下降

By

-- 周三午盘交易中,原油期货价格上涨,受霍尔木兹海峡集装箱船遭枪击事件报道以及美国燃料库存降幅超出预期的提振。 近月西德克萨斯中质原油期货价格上涨3.57%,至每桶92.87美元;布伦特原油期货价格上涨3.22%,至每桶101.65美元。 美国能源信息署(EIA)周三发布的周报显示,截至4月17日当周,美国原油库存增加190万桶,至4.657亿桶。EIA表示,目前原油库存比五年同期平均水平高出约3%。 该机构还表示,美国汽油库存减少460万桶,至2.284亿桶;馏分油库存减少340万桶,至1.081亿桶。 盛宝银行策略师援引维多集团的数据称,“油价和燃料价格上涨已导致约500万桶/日的需求下降。” 分析师表示,成品油市场压力依然明显,柴油、航空煤油和石化原料的短缺持续支撑着价格。 美国和伊朗在包括德黑兰核能力和以色列与黎巴嫩真主党战争在内的几个关键问题上仍僵持不下。 三菱日联银行研究分析师金秀珍表示,由于包括核问题和地区冲突在内的关键争端尚未解决,石油市场仍然高度关注地缘政治发展,并受到持续供应中断的支撑。 伊朗革命卫队称,其海军部队周三拦截了两艘试图穿越霍尔木兹海峡的船只,并将它们引导至伊朗领海。MarineTraffic表示,这两艘船均由地中海航运公司(MSC)运营。 袭击事件发生几天前,美军拦截并登船检查了一艘受制裁的油轮。此前,美军周末扣押了一艘货船,并表示已指示29艘船只返回港口,华盛顿方面正加大力度破坏伊朗的航运网络。 英国海事贸易行动部门称,至少有三艘船只在霍尔木兹海峡遭到枪击。与此同时,伊朗革命卫队警告称,任何破坏这条战略水道秩序和安全的行为都将被视为“红线”。 此外,特朗普在社交媒体上发文称,如果美国解除封锁开放霍尔木兹海峡,就永远不可能与伊朗达成协议。 美国总统表示,停火协议将继续有效,直到“严重分裂”的伊朗领导层能够提出一项统一的永久解决方案。然而,伊朗指责美国违反了其在脆弱的停火协议之初提出的十点框架下的承诺。

Related Articles

Equities

Canada's Retail Sales Momentum May Fade Later in The Year, Says National Bank

Statistics Canada's advance estimate points to a 0.6% month-over-month nominal increase in March retail sales, said National Bank of Canada after Friday's data.Given the surge in gasoline prices that occurred in the month, this figure heavily reflects higher prices at the pump. As a result, in real terms, retail sales could register a contraction in the final month of Q1, noted the bank.Nonetheless, for the quarter, information received to date indicates that real retail sales could grow at a 4.7% annualized pace, following a 2.0% decline in the previous quarter -- marking the strongest quarterly performance since Q4 2024, stated National Bank.This is all the more impressive as it is occurring against a backdrop of demographic contraction, pointed out the bank.Indeed, the most recent figures from StatsCan indicate that the country's population declined for a second consecutive quarter -- an unprecedented development.As a result, real retail spending per capita is tracking a 5.2% increase in Q1, a rebound from the sluggish prints seen in 2025. Still, National Bank thinks that this momentum could fade fast as the year progresses.As a result of the conflict in the Middle East, households will face an erosion in purchasing power in the coming months. This, combined with a mortgage interest-payment shock and a still fragile labor market, could weigh on discretionary spending going forward, according to the bank.

$$CXY
Australia

Cinemark Likely to Benefit From Release Slate, Wedbush Says

Cinemark (CNK) is set to benefit from a more consistent release slate over the next several quarters and further market share gains, Wedbush said in a Monday note."The summer slate, especially in Q3, is shaping up very nicely," the report said.The note said theater investments, including laser projectors, premium seats and screens, IMAX expansion, and strategic pricing could drive market share gains. It also pointed to other benefits such as new builds and returning cash to shareholders.For its Q1 results due May 1, Wedbush expects Cinemark to post Q1 revenue of $638 million, against consensus of $629 million, and a loss of $0.03 per share, against consensus of $0.16 loss.Wedbush kept its outperform rating and a $37 price target.Price: $29.40, Change: $+0.92, Percent Change: +3.23%

$CNK
Asia Markets

Swiss Market Index Closes Little Changed; Santhera Shares Jump

The blue-chip Swiss Market Index was down 0.03% on Monday's close, as investors gear up for a busy week of corporate updates, economic data prints and key monetary policy decisions.Santhera Pharmaceuticals (SANN.SW) secured a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use to expand the approval of its Duchenne muscular dystrophy drug Agamree to include the treatment of children who are at least two years old. The drug is currently approved for use on patients aged four and above. The Swiss specialty pharmaceutical company's shares gained 8.38% at closing.Meanwhile, RBC Capital Markets reiterated its outperform rating on Lonza Group (LONN.SW), with a price target of 670 francs, amid expectations that the Swiss pharmaceutical manufacturer's upcoming first-quarter update would be "uneventful." At the end of the trading day, the stock was up 1.83%."We do not see the Q1 qualitative update on 8 May to be a major catalyst for the stock now that Vacaville-specific commentary will no longer be provided, and any further weakness in Specialized Modalities should not be a surprise. We have also taken the opportunity to refresh and add to our commercial product (Enflonsia) and pipeline trackers. There has been some clinical progress, but consensus forecasts have been pushed out a little (aggregate peak sales estimates are unchanged)," the research firm said, noting that it views Lonza as an "attractive and undervalued compounding investment story."The local economic news calendar was empty for the day, while the release of the Swiss KOF Economic Barometer and the UBS & CFA Society Switzerland's economic sentiment index for April, as well as the country's March retail sales figures are on the agenda over the coming days. Market watchers are also awaiting the rate decisions of the US Federal Reserve, the European Central Bank, and the Bank of England.

$^SSMI$LONN.SW$SANN.SW